US FDA approves Bronchitol (mannitol) inhalation powder as add-on maintenance therapy to improve pulmonary function in adult patients with cystic fibrosis (CF)

Approval was based on 3 RCTs (n=761) which showed mannitol use led to a sustained improvement in FEV1 vs. control over a 26-week treatment period; most common adverse reactions, occurring in 3% or more of patients, included cough and haemoptysis.

Source:

Biospace Inc.